Pharmacokinetic optimisation of the treatment of cancer with high dose zidovudine

Clinical Pharmacokinetics

Volumn 34, Issue 2, 1998, Pages 173-180

  Danesi, Romano ^a,b,c   Falcone, Alfredo ^a   Conte, Pier Franco ^a   Del Tacca, Mario ^b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; COLON CANCER; DNA STRAND BREAKAGE; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; HUMANS; NEOPLASMS; ZIDOVUDINE;

EID: 0031931847     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199834020-00005     Document Type: Article

References (24)

1. Horowitz JP, Chua J, Noel MJ. Nucleosides v the monomesylates of 1-(2α-deoxy-β-D-lyxofuranosyl)thymines. Org Chem Ser Monogr 1964; 29: 2076-8
2. Wilde MI, Langtry HD. Zidovudine: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993; 46 (3): 515-78
3. Barry M, Howe JL, Ormesher S, et al. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. Br J Clin Pharmacol 1994; 37 (5): 421-6
4. Kong XB, Zhu QY, Vidal PM, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 1992; 36 (4): 808-18
5. Peter K, Gambertoglio JG. Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus. Clin Pharmacol Ther 1996; 60 (2): 168-76
6. Mukherji E, Au JL, Mathes LE. Differential antiviral activities and intracellular metabolism of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine in human cells. Antimicrob Agents Chemother 1994; 38 (7): 1573-9
7. Bebenek K, Thomas DC, Roberts JD, et al. Effects of 3′-azido-3′-deoxythymidine metabolites on simian virus 40 origin-dependent replication and heteroduplex repair in HeLa cell extracts. Mol Pharmacol 1993; 43 (1): 57-63
8. Tornevik Y, Ullman B, Balzarini J, et al. Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem Pharmacol 1995; 49 (6): 829-37
9. Darnowski JW, Davol PA, Goulette FA. Human recombinant interferon alpha-2a plus 3′-azido-3′-deoxythymidine. Synergistic growth inhibition with evidence of impaired DNA repair in human colon adenocarcinoma cells. Biochem Pharmacol 1997; 53 (4): 571-80
10. Bouayadi K, Hoffmann JS, Fons P, et al. Overexpression of DNA polymerase beta sensitizes mammalian cells to 2′,3′-deoxycytidine and 3′-azido-3′-deoxythymidine. Cancer Res 1997; 57 (1): 110-16
11. Darnowski JW, Goulette FA. 3′-Azido-3′-deoxythymidine cytotoxicity and metabolism in the human colon tumor cell line HCT-8. Biochem Pharmacol 1994; 48 (9): 1797-805
12. Wagner CR, Ballato G, Akanni AO, et al. Potent growth inhibitory activity of zidovudine on cultured human breast cancer cells and rat mammary tumors. Cancer Res 1997; 57 (12): 2341-5
13. Brunetti F, Falcone A, Calabresi P, et al. 5-Fluorouracil enhances azidothymidine cytotoxicity: in vitro, in vivo, and biochemical studies. Cancer Res 1990; 50 (13): 4026-31
14. Andreuccetti M, Allegrini G, Antonuzzo A, et al. Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA induced strand breaks. Eur J Cancer A 1996; 32A (7): 1219-26
15. Tosi P, Calabresi P, Goulette FA, et al. Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo. Cancer Res 1992; 52 (15): 4069-73
16. Pressacco J, Erlichman C. Combination studies with 3′-azido-3′-deoxythimidine (AZT) plus ICID1694. Cytotoxic and biochemical effects. Biochem Pharmacol 1993 Dec; 46 (11): 1989-92
17. Tosi P, Visani G, Ottaviani E, et al. Hydroxyurea enhances 3′-azido-3′-deoxythymidine (AZT) cytotoxicity in human chronic myeloid leukemia models. Eur J Haematol 1994; 52: 1291-5
18. Marchbanks K, Dudley MN, Posner MR, et al. Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. Pharmacotherapy 1995; 15 (4): 451-7
19. Posner MR, Darnowski JW, Calabresi P, et al. Oral zidovudine, continuous infusion fluorouracil, and oral leucovorin calcium: a phase I study. J Natl Cancer Inst 1990; 82 (21): 1710-4
20. Posner MR, Darnowski JW, Weilberg AB, et al. High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial. Cancer 1992; 70 (12): 2929-34
21. Beitz JG, Damowski JW, Cummings FJ, et al. Phase I trial of high-dose infused zidovudine combined with leucovorin plus fluorouracil. Cancer Invest 1995; 13 (5): 464-9
22. Clark J, Sikov W, Cummings F, et al. Phase II study of 5-fluorouracil, leucovorin and azidothymidine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 1996; 122 (9): 554-8
23. Falcone A, Danesi R, Dargenio F, et al. Intravenous azido-thymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. J Clin Oncol 1996; 14 (3): 729-36
24. Falcone A, Lencioni M, Brunetti I, et al. Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells. Ann Oncol 1997; 8 (6): 539-45